Effect of parathyroid hormone administration in a patient with severe hypoparathyroidism caused by gain-of-function mutation of calcium-sensing receptor.
Hypoparathyroidism caused by gain-of-function mutations of the calcium-sensing receptor (CaR) in the transmembrane domain is usually severe and difficult to manage. A patient with severe hypoparathyroidism, caused by CaR activating mutation F821L, was treated for 3 days (Day 1 to Day 3) with synthetic human parathyroid hormone 1-34 (teriparatide, PTH). An Ellsworth-Howard test of the patient revealed normal responses of urine phosphate and cyclic AMP excretion, indicating that the patient's renal tubules normally responded to extrinsic PTH. On Day 1 to Day 3, 0.9 microg/kg/day of PTH was administered subcutaneously twice daily at 0800 and 2000. On Day 1, the serum calcium level that was 1.8 mmol/l before PTH administration increased to 2.1 mmol/l at 1200, and gradually decreased to 1.8 mmol/l at 2000. On Days 2 and 3, the maximum calcium levels were 2.5 and 2.4 mmol/l, respectively, at 1200. At 2000, they returned to or below basal levels at 0800. On Day 4 without PTH administration, the calcium levels were maintained at the basal levels at Day 0. The urine calcium/creatinine (Ca/Cr) ratio that was high (>0.4) before PTH injection decreased after PTH administration (0.4>). Changes in the ionized calcium levels were almost parallel with the total calcium levels. The serum inorganic phosphate (IP) level decreased to 2.4 mmol/l at 1000, but gradually increased before the second PTH injection to the level at 0800 on Day 1. The minimum IP level on Days 2 and 3 was 2.1 mmol/l and 2.0 mmol/l, respectively. In contrast to the remarkable changes in the serum calcium level by PTH treatment, the serum magnesium levels showed few changes. These results indicate that PTH therapy could be effective in correcting serum and urine calcium and the phosphate levels in hypoparathyroidism caused by activating mutation of CaR.
Shiohara
Masaaki
M
Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Shiozawa
Riyo
R
Kurata
Kenji
K
Matsuura
Hiroki
H
Arai
Fumi
F
Yasuda
Toshiyuki
T
Koike
Kenichi
K
D002118:Calcium / Q000097:blood; D002648:Child; D003404:Creatinine / Q000097:blood; D000242:Cyclic AMP / Q000652:urine; D006801:Humans; D007011:Hypoparathyroidism / Q000097:blood / Q000188:drug therapy* / Q000235:genetics* / Q000652:urine; D008274:Magnesium / Q000097:blood; D008297:Male; D009154:Mutation; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000652:urine; D044169:Receptors, Calcium-Sensing / Q000235:genetics*; D019379:Teriparatide / Q000627:therapeutic use*
C470125:PTH protein, human; D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing; D019379:Teriparatide; D010758:Phosphorus; D003404:Creatinine; D000242:Cyclic AMP; D008274:Magnesium; D002118:Calcium